SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as essential decentralized finance infrastructure, bolstered by a recent partnership with the U.S. Department of Commerce to provide macroeconomic data on-chain. The community is actively discussing the project's strong institutional backing, revenue-sharing model through token buybacks, and its growing importance within the Real World Asset (RWA) sector.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The 4CHAN token is trending as a cultural index, with community members branding it the "Bitcoin of memecoins" due to its origins as the birthplace of major internet memes. While some retail traders are debating its volatility and long-term potential, the community is actively encouraging others to accumulate during market dips and hold through structural price fluctuations.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing community attention as traders highlight its recent price resilience and YTD outperformance against Bitcoin, fueling speculation of a major breakout. Conversations are dominated by anticipation for the upcoming 2026 'Layla' network upgrade, with many users debating its potential to reclaim status as a top-tier peer-to-peer electronic cash platform while others remain skeptical of its long-term momentum.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is trending as investors weigh strong earnings and high-growth potential in its immunology and oncology pipelines against ongoing regulatory scrutiny at a third-party manufacturing facility. Community sentiment remains mixed, with bullish long-term investors pointing to strong fundamentals and potential label expansions, while traders express frustration over the stock's volatility and recent supply-chain related delays.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is currently navigating market volatility following Merck's announcement that the combination of Welireg and Lenvima outperformed Exelixis's Cabometyx in a key Phase 3 trial for renal cell carcinoma. While investors weigh the potential loss of market share in the second-line treatment setting against the company's established revenue, the community remains divided between those focused on the stock's growth potential and those concerned about increased competitive pressure.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina Inc

Illumina is trending as investors react to the company's long-term strategy for operational efficiency and value creation, even as it navigates significant headwinds from international trade tensions and a ban on its gene sequencers in China. The community remains divided, with some highlighting the stock's potential as a leader in precision medicine and genomics data, while others express caution regarding the company's slowing revenue growth and its high valuation relative to current performance.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors debate the potential for a recovery amid active discussions about its decentralized AI agent infrastructure and recent volatility. The community remains polarized, with some focused on long-term utility and accumulation opportunities while others express frustration over price performance and the ongoing fallout from the ASI merger.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals remains a focal point for investors as the biotech sector evaluates RNA interference leadership, with active community discussion centered on both the company's strong commercial pipeline and the broader competitive landscape of genetic medicine. Market participants are closely watching the companys ongoing clinical developments and potential strategic collaborations as catalysts that could influence its long-term growth trajectory.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy is experiencing significant volatility driven by a major earnings miss and investor caution ahead of potential equity dilution, while the long-term bullish thesis remains centered on its role as the only licensed U.S. producer of HALEU fuel for critical nuclear infrastructure. The community is actively debating the company's valuation versus its strategic necessity, with many traders focused on technical support levels and the potential for a recovery as the sector benefits from sustained federal funding and increasing energy demands from AI data centers.

EQT Corp. is a natural gas production company, which engages in the provision of supply, transmission, and distribution of natural gas. The company was founded in 1888 and is headquartered in Pittsburgh, PA.

EQT Corp

EQT Corp is drawing investor attention as it reports a significant earnings beat and raises production guidance, highlighting strong operational efficiency and cost management. The community is actively debating the company's long-term value proposition as it positions itself to capitalize on growing natural gas demand from AI data centers and evolving infrastructure needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mak Capital One LLC Buys 9,062,518 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Mak Capital One LLC lifted its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 53.5% in the third quarter, according to the company in its most recent disclosure with...

Autolus Therapeutics (AUTL) Projected to Post Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026

Autolus Therapeutics (NASDAQ:AUTL) Chief Executive Officer Christian Itin told conference attendees the company is entering its second year as a commercial-stage business following the launch of its...

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Hold" by Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Hold" from the seven brokerages that are presently covering the stock...

Traders Buy Large Volume of Autolus Therapeutics Call Options (NASDAQ:AUTL)

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) was the target of unusually large options trading activity on Monday. Traders purchased 2,496 call options on the stock. This...

Q1 Earnings Forecast for AUTL Issued By HC Wainwright

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Autolus Therapeutics in a research report issued...

What is HC Wainwright's Estimate for AUTL FY2025 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Investment analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Autolus Therapeutics in...

Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Strong-Buy at HC Wainwright

HC Wainwright raised shares of Autolus Therapeutics to a "strong-buy" rating in a report on Tuesday...

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Hold" by Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the stock, Marketbeat...

New Strong Sell Stocks for January 30th

TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026.

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

AUTL
Autolus Therapeutics Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUTL News

AUTLAutolus Therapeutics Ltd - ADR